Match!
Fabienne Gonçalves
Physical therapyCambridge Pulmonary Hypertension Outcome ReviewPulmonary hypertensionDiabetes mellitusMedicine
15Publications
3H-index
30Citations
What is this?
Publications 16
Newest
Source
Source
#1Mário Santos (University of Porto)H-Index: 13
#2Ana P. GomesH-Index: 21
Last. Abílio ReisH-Index: 4
view all 10 authors...
Abstract Objectives This study aims to assess the long-term survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients followed in a Portuguese pulmonary hypertension (PH) referral center. Methods We studied PAH and CTEPH patients diagnosed between January 2005 and December 2016. Cumulative survival was estimated using the Kaplan-Meier method. Survival trends were compared over two periods (2005-2010 vs. 2011-2016). Results Of the 142 stu...
Source
#1Ana P. GomesH-Index: 21
#2Célia F. CruzH-Index: 5
Last. Abílio ReisH-Index: 4
view all 10 authors...
Abstract Background Pulmonary hypertension (PH) is a heterogeneous, debilitating condition with highly relevant impact on functional capacity, quality of life, and life-expectancy. Objectives This study aims to provide long-term data on the Portuguese PH population, by characterising the clinical presentation, evolution, and outcomes of PH patients in a specialised referral centre. Methods Retrospective analysis of a cohort of 101 patients with pre-capillary PH (pcPH) referenced to an expert ter...
1 CitationsSource
#1Abílio ReisH-Index: 4
#2Mário SantosH-Index: 13
Last. Luis Almeida (University of Porto)H-Index: 38
view all 10 authors...
Background. Health-related quality of life (HRQoL) impairment is common in pulmonary hypertension (PH), but its clinical predictors are not well established. This study aims to characterize the HRQoL of patients with pulmonary arterial hypertension (PAH) and other precapillary forms of PH (pcPH) and to explore its clinical correlates. Materials and Methods. A cross-sectional, observational study of patients with documented PAH and other forms of pcPH. Patients completed two patient-reported outc...
Source
#1Mário SantosH-Index: 13
Last. Abílio ReisH-Index: 4
view all 4 authors...
Introduction: In addition to several pharmacodynamics advantages over bosentan, macitentan has once-a-day profile, less liver toxicity and drug interactions, and outcome data showing improved mortality and morbidity in pulmonary arterial hypertension (PAH) patients. We aimed to examine the effect of switching bosentan to macitentan on clinical status of PAH patients. Methods and Results: We conducted a retrospective observational study in a cohort of 32 patients with PAH that transitioned from b...
Source
#1Abílio ReisH-Index: 4
#2James TwissH-Index: 12
Last. Luis AlmeidaH-Index: 38
view all 9 authors...
Source
#1Abílio ReisH-Index: 4
#2James TwissH-Index: 12
Last. Luis Almeida (University of Aveiro)H-Index: 38
view all 9 authors...
Background Patients with pulmonary arterial hypertension (PAH) and other forms of precapillary pulmonary hypertension (PH) have impaired quality of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a PH-specific patient-reported outcome measure that assesses symptoms, activity limitations and QoL. It was originally developed in UK-English. The main objective of this study was to create an adaptation of the CAMPHOR suitable for a Portuguese-speaking population.
4 CitationsSource
Introduction: The 6-minute walk distance (6MWD) is an important clinical endpoint in pulmonary arterial hypertension (PAH). Objective: To study the incremental prognostic value of oxygen saturation (SO2) changes during a walk test in PAH. Methods: Baseline and final SO2 (ΔSO2) data, as well as 6MWD from the walk test at the time of diagnosis of 115 incident PAH patients were collected. Cox proportional hazards models were used to study the relationship between ΔSO2 and the composite outcome (hea...
Source
#2Ana GomesH-Index: 6
Last. Abílio ReisH-Index: 4
view all 8 authors...
Background: Phosphodiesterase type-5 inhibitors (iPDE5) are one of the mainstays of Pulmonary Arterial Hypertension (PAH) treatment. Tadalafil is an alternative to sildenafil with the advantage of a less frequent dosing (once instead of 3-times daily). Aim: To examine the feasibility of transitioning PAH patients from sildenafil to taladafil. Methods: We studied twenty clinically stable PAH outpatients from a single pulmonary vascular disease centre receiving sildenafil that were transitioned to...
Source
12